Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 65 years of age~* Negative test for the selected drugs of abuse at screening~Hepatic impaired subjects:~* Stable hepatic function and medication regimen for at least 28 days prior to check-in~* Degree of hepatic impairment will be determined by the Child-Pugh Scale~Exclusion Criteria:~* Clinical manifestation of any disease (except hepatic impaired subjects)~* History of significant hypersensitivity, intolerance, or allergy to any drug compound, including food, or other substance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with moderate chronic hepatic impairment (Type: EXPERIMENTAL): Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
- Healthy subjects matched to moderate hepatic impaired subjects (Type: EXPERIMENTAL): Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
- Subjects with mild chronic hepatic impairment (Type: EXPERIMENTAL): Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
- Healthy subjects matched to mild hepatic impaired subjects (Type: EXPERIMENTAL): Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
- Subjects with severe chronic hepatic impairment (Type: EXPERIMENTAL): Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).